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The article by Gerdt and colleagues in this issue of Chemistry & Biology provides molecular insights into how
nonlactone quorum sensingmodulators either activate or deactivate LasR. Interestingly, an antagonist could
flip into an agaonist upon mutation of a single residue in the autoinducer binding site.Isolationists rarely make headways in life,
because it is often rewarding and benefi-
cial for an individual to communicate
with peers or even nonpeers and coordi-
nate behaviors that are beneficial to a
whole group. Some bacteria communi-
cate via small diffusible molecules, called
autoinducers, to coordinate group behav-
iors. This communication process, called
quorum sensing (QS) (Fuqua et al.,
1994), is found in both Gram-negative
and Gram-positive bacteria and is used
to control processes as diverse as biolu-
minescence, pigmentation, virulence fac-
tor production, and biofilm formation,
among others. Due to the importance of
QS in pathogenesis, interest in developing
small molecules that could attenuate the
QS process is high (Galloway et al.,
2011; Guo et al., 2013).
The three main types of QS autoin-
ducers are cyclic peptides (used by
Gram-positive bacteria), N-acyl L-homo-
serine lactone (AHL or AI-1, used by
Gram-negative bacteria) and (4S)-4,5-
dihydroxypentane-2,3-dione-derived iso-
mers (collectively called AI-2, used by
both Gram-negative and Gram-positive
bacteria). Of the three main QS signaling
types, the AHL system in Gram-negative
bacteria has been the most extensively
studied and characterized. AHL-based
QS in Gram-negative bacteria can be
categorized into three main components:
the signal generator (LuxI-type synthase);
the AHL signal itself (made up of a lactone
head group and acyl tail), and the signal
receptor (LuxR-type transcriptional regu-
lator). All of these three basic components
could be targeted to modulate QS, but so
far the majority of efforts to develop an-
tagonists of AHL signaling have focused
on the inhibition of LuxR-type signal re-
ceptor (Galloway et al., 2011). LasR, atranscriptional regulator found in Pseudo-
monas aeruginosa, is a LuxR-type protein
and has garnered significant interest as
an antivirulence target. P. aeruginosa is
an opportunistic pathogen that colonizes
and forms biofilms in the lungs of patients
with cystic fibrosis, and it has been
demonstrated that LasR-mediated QS
partly contributes to the pathogenesis
of P. aeruginosa (Tang et al., 1996).
When the concentration of the cognate
LasR autoinducer, N-(3-oxo)-dodecanoyl
L-homoserine lactone (OdDHL; Figure 1),
reaches a certain threshold, LasR binds
to the autoinducer and becomes stabi-
lized. The LasR homodimer-ligand com-
plex then binds to promoter regions to
activate transcription via the recruitment
of the transcriptional machinery. The ma-
jority of LasR ligands developed to date
are AHL mimics and have an intact
lactone head group and modified fatty
acid tail or vice versa (Galloway et al.,
2011). The fatty acid tail portion of LasR li-
gands dictates whether a ligand activates
or inactivates LasR. An important study
by Chen et al. on a related protein, CviR,
has provided a model for how the acyl
chain of lactone-based ligands affects
the activity of LuxR-type proteins (Chen
et al., 2011). This work showed that subtle
interactions between the acyl tail of
lactone-based antagonists and Met89 of
CviR caused each of the DNA-binding do-
mains (DBD) of the homodimer to interact
with the ligand-binding domain (LBD) of
the other monomer. Met89 lies at the
LBD-DBD interface, and this explains its
role in modulating the protein-protein
interaction in CviR. Upon antagonist bind-
ing, the interaction between the LBD and
DBD of the CviR homodimer leads to a
splaying of the DNA binding domains,
and this conformer is unable to bind toChemistry & Biology 21, October 23, 2014the operator (Chen et al., 2011). It is likely
that the DBD splaying mechanism occurs
in other LuxR-type proteins, such as
LasR.
The activation or inhibition of LasR by
AHL mimics does not depend only on
the acyl tail but also the head group. In
some instances very minor modifications
to a ligand could result in a dramatic
switch from agonism to antagonism or
vice versa. For example, lactone 2 and thi-
olactone 3 are only marginally different
from each other (Figure 1), yet they have
diametrically opposite effects on LasR; 2
is an inhibitor of LasR, whereas 3 is an
activator of LasR (Geske et al., 2007;
McInnis and Blackwell, 2011). The molec-
ular basis for this interesting switch had
not been fully delineated until now. Earlier
work by Suga had suggested that Trp60 in
the OdDHL-binding site of LasR was key
to determining if a ligand acted as an in-
hibitor (Jog et al., 2006). This study was
done before the crystal structure of
OdDHL-LasR became available, so the
authors were limited in advancing the
Trp60 interaction model. The crystal
structure of OdDHL-LasR is now available
(Bottomley et al., 2007), and this has facil-
itated a more in-depth analysis of the role
played by Trp60 and other OdDHL-bind-
ing site residues inmodulating LasR activ-
ity. In a report in this issue of Chemistry &
Biology, Gerdt et al. (2014) use computa-
tional docking, binding site mutagenesis,
and reporter assays to demonstrate quite
beautifully that unfavorable interaction
between Trp60 and non-lactone-based
QS modulators dictates the inactivation
of LasR. The authors mutated every resi-
due in the OdDHL-binding site of LasR
and assayed the activities of these mu-
tants, using both lactone and nonlactone
ligands. This study has revealed that theª2014 Elsevier Ltd All rights reserved 1261
AB
Figure 1. Wild-Type and W60F Mutant LasR-Mediated Quorum Sensing in P. aeruginosa
(A) Wild-type LasRmonomers dimerize upon OdDHL binding. Activated LasR dimer recruits the transcrip-
tion machinery and induces gene transcription, such as a b-galactosidase reporter. When the nonlactone
ligand 1 binds to LasR, the amide in the aniline head group clashes with Trp60 and leads to the formation of
inactive LasR dimer. Ligand 1 acts as antagonist and competes with OdDHL for LasR, so b-galactosidase
gene expression level is low.
(B) LasR W60F is compatible with both OdDHL and ligand 1. LasR binding to both ligands can lead to
active dimers.
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QS modulator depends on interplay
between ligand head group size and
Trp60, which is highly conserved in
LuxR-type proteins. Larger head groups
in nonlactone QS modulators engage in
unfavorable interactions with the Trp60
residue, leading to inactivation of the
LasR protein. Interestingly when a large
head group clashes with the Trp60 resi-
due, mutating this residue into a smaller
Phe60, could eliminate the unfavorable
ligand-residue interaction and flip the
ligand from being an antagonist to an
agonist, a bump-hole approach (Bishop
et al., 2000). An illustrative example is
the nonlactone ligand aniline ligand 11262 Chemistry & Biology 21, October 23, 20(Figure 1), which is an antagonist against
wild-type LasR, presumably via unfavor-
able steric interactions between the ani-
line head group and Trp60 residue, but
is an agonist for W60F LasR mutant, a
Janus-type behavior. Residues Tyr56
and Ser129 are also key determinants of
ligand activity switch in LasR. Y56F muta-
tion could flip compound 1 from an antag-
onist to an agonist and S129A mutant
could flip the activity of compound 3
from an agonist to an antagonist. Both
Tyr56 and Ser129 form hydrogen bonds
with the carbonyl moiety of OdDHL and
are hypothesized to position ligands
near the Tyr residue. The involvement of
these residues in the Janus-type behavior14 ª2014 Elsevier Ltd All rights reservedcould arise from their involvement in
steering the head groups of nonlactone
QS modulators toward or away from the
critical Trp60 residue.
Gerdt et al.’s report is important for
several reasons. It is the first demonstra-
tion that a ‘‘bump-hole’’ approach can be
used to tailor the activity of a nonlactone
QS modulator. Before this work, there
were no solid principles to guide the
design hydrolytically stable AHL mimics,
so insights from this work are certainly
going to be useful for future LasR ligand
design. Additionally, this work contrib-
utes to the current understanding of
how bacteria could become resistant to
anti-QS drugs via response regulator
mutation (Chen et al., 2011). Critically it
demonstrates that QS resistance could
be an active process, in that the resis-
tance mechanism could actually turn
the anti-QS drug into a QS activator,
and this would exacerbate an infection.
This Janus-type behavior can be likened
to a worst-case battlefield scenario
whereby friendly fires become the
norm. We should however take solace
in the fact that resistance that emerges
toward QS inhibitors do not spread as
efficiently as traditional antibiotic-based
bacterial resistance (Mellbye and Schus-
ter, 2011).
Finally the LasR mutants (W60F, Y56F,
and S129A) and analogous LuxR type
mutants that could be engineered to
show Janus-like behavior could find
utility in complex genetic circuits that
require orthogonal and inducible genetic
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